Premium
Identification of high‐risk stage II and stage III colorectal cancer by analysis of MMP‐21 expression
Author(s) -
Wu Tao,
Li Yi,
Liu Xiaohong,
Lu Jianguo,
He Xianli,
Wang Qing,
Li Jipeng,
Du Xilin
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21970
Subject(s) - colorectal cancer , medicine , stage (stratigraphy) , oncology , metastasis , immunohistochemistry , cancer , matrix metalloproteinase , pathology , cancer research , biology , paleontology
Background The expression of matrix metalloproteinase‐21 (MMP‐21) has been shown to be elevated in some solid tumor and thought to enhance tumor invasion and metastasis ability. In the present study, we investigated the expression of MMP‐21 and its association with prognosis in stage II and III colorectal cancer. Methods MMP‐21 expression was investigated in 286 cases of colorectal cancer by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of MMP‐21 expression with clinicopathological characters and overall survival of patients with stage II and III colorectal cancer. Results MMP‐21 expression was significantly higher in colorectal cancer, compared with that in normal epithelial tissue. And it also correlated with tumor invasion, lymph node metastasis, and distant metastasis of colorectal cancer. MMP‐21 was also proved to be an independent prognostic factor in patients with stage II as well as stage III colorectal cancer. However, no correlations between MMP‐21 expression and patients' age, sex, tumor location, or differentiation status were detected. Conclusion These results suggested the potential role of MMP‐21 in the invasion and metastasis process of human colorectal cancer. It could also be a novel molecular marker to predict prognosis of patients with stage II and stage III colorectal cancer. J. Surg. Oncol. 2011; 104:787–791. © 2011 Wiley Periodicals, Inc.